Possibilities of respiratory viral infections therapy under the conditions of etiological diversity

The problem of the combined development and interconnection of ARVI and influenza-related parasitic systems occupies more and more space in the theory and practice of epidemic research. Occurrence of the upper respiratory tract pathologies caused by seasonal mixed circulation of influenza viruses and other acute respiratory viral infections in humans is of great concern now. Use of interferon inducers as antiviral and immunomodulating agents is an important approach to the treatment of acute respiratory viral infections.

Aim and methods of the research. Estimation of the incidence of acute respiratory viral infections and grippe in Saint Petersburg and the Kaliningrad region, as well as an estimation of vaccination as a factor influencing a self-regulating epidemic process was performed within the framework of this study. Use of an interferon inducer with various methods of administration in patients with diagnoses «ARVI» and «influenza» of moderate severity with an uncomplicated clinical course was studied.

Results and conclusion. Active co-circulation of numerous ARVI pathogens (influenza viruses, adenoviruses, parainfluenza viruses, metopneumovirus, bocavirus, coronavirus, etc.) was fixed. Such a large number and heterogeneity of ARVI pathogens requires the use of medicines that actively affect the entire group of viruses. The type of reported morbidity associated with respiratory viruses is very diverse and has undergone a pronounced transformation in recent years. At the same time, active vaccination against influenza leads to changes in the course of the annual epidemic seasons for influenza and ARVI. A promising interferon inducer has been identified; it increases the body’s resistance to infectious effects and can be successfully used to treat viral respiratory infections.